monrd0027
Medals oligonucleic drug ID monrd0027
ATC Classification -
Product Name Mongersen
Synonims GED-0301
Country US
Italy
Company Celgene Corporation
GIULIANI
phase III
Type Antisense
Adaptation Diseases Crohn’s disease
Target Molecule SMAD7
Remarks Mongersen is a drug under development treating inflammation associated with Crohn's disease.
As a result of double-blind, placebo-controlled phase II study on patients with Crohn's disease, the remission rate and clinical response were significantly higher compared to the placebo control group.
A phase III study has been carried out.
Nucleic Acid Sequence -
Source https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001963-37/LV,
http://www.nejm.org/doi/full/10.1056/NEJMoa1407250,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-002640-27/IT,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-001925-18/GB,
http://www.nejm.org/doi/full/10.1056/NEJMoa1407250
DrugBank -
TargetProtein - UniProt O15105
TargetProtein - PDB 2LTW